JP2016516723A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516723A5
JP2016516723A5 JP2016503109A JP2016503109A JP2016516723A5 JP 2016516723 A5 JP2016516723 A5 JP 2016516723A5 JP 2016503109 A JP2016503109 A JP 2016503109A JP 2016503109 A JP2016503109 A JP 2016503109A JP 2016516723 A5 JP2016516723 A5 JP 2016516723A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516723A (ja
JP6769865B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029479 external-priority patent/WO2014144885A2/en
Publication of JP2016516723A publication Critical patent/JP2016516723A/ja
Publication of JP2016516723A5 publication Critical patent/JP2016516723A5/ja
Application granted granted Critical
Publication of JP6769865B2 publication Critical patent/JP6769865B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503109A 2013-03-15 2014-03-14 ガンワクチン及びそれを用いた治療方法 Active JP6769865B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799952P 2013-03-15 2013-03-15
US61/799,952 2013-03-15
PCT/US2014/029479 WO2014144885A2 (en) 2013-03-15 2014-03-14 Cancer vaccines and methods of treatment using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019026468A Division JP7256024B2 (ja) 2013-03-15 2019-02-18 ガンワクチン及びそれを用いた治療方法

Publications (3)

Publication Number Publication Date
JP2016516723A JP2016516723A (ja) 2016-06-09
JP2016516723A5 true JP2016516723A5 (enExample) 2017-03-30
JP6769865B2 JP6769865B2 (ja) 2020-10-14

Family

ID=51538388

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016503109A Active JP6769865B2 (ja) 2013-03-15 2014-03-14 ガンワクチン及びそれを用いた治療方法
JP2019026468A Active JP7256024B2 (ja) 2013-03-15 2019-02-18 ガンワクチン及びそれを用いた治療方法
JP2021038385A Pending JP2021100944A (ja) 2013-03-15 2021-03-10 ガンワクチン及びそれを用いた治療方法
JP2022184046A Pending JP2023021127A (ja) 2013-03-15 2022-11-17 ガンワクチン及びそれを用いた治療方法
JP2025102558A Pending JP2025129169A (ja) 2013-03-15 2025-06-18 ガンワクチン及びそれを用いた治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019026468A Active JP7256024B2 (ja) 2013-03-15 2019-02-18 ガンワクチン及びそれを用いた治療方法
JP2021038385A Pending JP2021100944A (ja) 2013-03-15 2021-03-10 ガンワクチン及びそれを用いた治療方法
JP2022184046A Pending JP2023021127A (ja) 2013-03-15 2022-11-17 ガンワクチン及びそれを用いた治療方法
JP2025102558A Pending JP2025129169A (ja) 2013-03-15 2025-06-18 ガンワクチン及びそれを用いた治療方法

Country Status (11)

Country Link
US (2) US11419925B2 (enExample)
EP (2) EP2968607B1 (enExample)
JP (5) JP6769865B2 (enExample)
KR (4) KR20210123426A (enExample)
CN (3) CN105025932B (enExample)
AU (5) AU2014228405B2 (enExample)
BR (1) BR112015022367B1 (enExample)
CA (1) CA2898126A1 (enExample)
EA (2) EA034110B1 (enExample)
MX (2) MX369709B (enExample)
WO (1) WO2014144885A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626238C (en) 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
PL2931304T3 (pl) * 2012-12-13 2021-11-08 The Trustees Of The University Of Pennsylvania Szczepionka wt1
CN110078813B (zh) 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2014144885A2 (en) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
CA3156357A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US20150374815A1 (en) 2014-06-25 2015-12-31 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
CN107427567A (zh) 2015-01-29 2017-12-01 宾夕法尼亚大学理事会 检查点抑制剂和疫苗组合物及其用于免疫疗法的用途
WO2016168361A1 (en) * 2015-04-14 2016-10-20 Polynoma, Llc Polyvalent vaccines and combination therapy for the treatment of melanoma
EP3359183B1 (en) * 2015-10-06 2020-06-17 Invectys Polyepitope constructs for use in immunotherapy
JP7148399B2 (ja) * 2015-11-04 2022-10-05 タイペイ・ベテランズ・ジェネラル・ホスピタル 悪性疾患に対する併用療法
SMT202200370T1 (it) * 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
ES2811523T3 (es) 2016-01-19 2021-03-12 Pfizer Vacunas contra el cáncer
EP3405203A4 (en) * 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
MX2018009506A (es) 2016-02-05 2019-05-06 Inovio Pharmaceuticals Inc Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
WO2017175200A1 (en) 2016-04-08 2017-10-12 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
HUE065176T2 (hu) 2016-06-02 2024-05-28 Ultimovacs Asa Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében
WO2018056825A1 (en) 2016-09-23 2018-03-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Manipulation of immune activity by modulation of expression
WO2018064588A2 (en) * 2016-09-30 2018-04-05 Weiner, David Tert immunogenic compositions and methods of treatment using the same
US11666646B2 (en) 2016-12-26 2023-06-06 National University Corporation Kobe University Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor
US11229668B2 (en) * 2017-02-07 2022-01-25 Nantcell, Inc. Maximizing T-cell memory and compositions and methods therefor
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
AU2018383658B2 (en) * 2017-12-13 2022-02-10 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
US11338029B2 (en) * 2017-12-13 2022-05-24 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting PRAME and uses thereof
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
TWI816603B (zh) 2018-04-23 2023-09-21 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
US11564980B2 (en) * 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
MX2020012649A (es) * 2018-05-25 2021-07-02 The Wistar Inst Neoantígenos especificos de tumor y métodos de uso de estos.
WO2020020444A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
WO2021051065A1 (en) * 2019-09-12 2021-03-18 Inovio Pharmaceuticals, Inc. Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same
JP2023510112A (ja) * 2019-12-19 2023-03-13 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー アフリカ豚熱ウイルスに対するワクチン、およびそれを使用する方法
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法
PH12022553102A1 (en) 2020-05-14 2023-11-20 Inovio Pharmaceuticals Inc Vaccines for recurrent respiratory papillomatosis and methods of using the same
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
CN114113611B (zh) * 2021-12-13 2023-07-14 郑州大学 一种用于肝癌诊断的生物标志物及检测试剂盒
EP4463151A4 (en) * 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy
US12558408B2 (en) 2022-03-08 2026-02-24 Immunitybio, Inc. Intratumorally injected yeast vaccine
CN115845039A (zh) * 2022-07-01 2023-03-28 可蓝赛生物医药(上海)有限公司 一种广谱多肽肿瘤疫苗组成
AU2023358768A1 (en) * 2022-10-13 2025-05-15 Inovio Pharmaceuticals, Inc. Vaccines for recurrent respiratory papillomatosis and methods of using the same
CN118141903B (zh) * 2024-03-11 2025-09-23 上海申锐联生物医药有限公司 一种治疗犬黑色素瘤的环状rna疫苗

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
AT400955B (de) 1989-03-08 1996-05-28 Health Research Inc Rekombinantes pockenvirus-wirtsselektionssystem
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1990011687A1 (en) 1989-03-31 1990-10-18 Washington University VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
WO1994016737A1 (en) 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU700371B2 (en) 1993-06-07 1999-01-07 Genentech Inc. Hiv envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US7501501B2 (en) * 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
CN1257976C (zh) 1996-10-23 2006-05-31 宾夕法尼亚州立大学托管会 改良疫苗
IL132103A0 (en) 1997-04-03 2001-03-19 Eletrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
BR0008645A (pt) * 1999-03-03 2002-01-22 Univ Pennsylvania Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição
US20030215425A1 (en) 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
EP1276896B1 (en) * 2000-04-28 2010-07-21 Mannkind Corporation Epitope synchronization in antigen presenting cells
CA2439492A1 (en) * 2001-02-26 2002-09-06 Imclone Systems Incorporated Tri-hybrid melanoma antigen
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US20030013637A1 (en) 2001-05-18 2003-01-16 Hideto Ikushima Novel anti-autoimmune composition by inhibition of GRF action
JP4273293B2 (ja) * 2001-05-18 2009-06-03 大日本住友製薬株式会社 Ｇｒｆ作用の阻害による新規抗自己免疫疾患剤、及びそのスクリーニング方法
EP1270732A1 (en) 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
AU2003249357A1 (en) * 2002-06-27 2004-01-19 Geron Corporation Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
EP2181595A1 (en) * 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
US7223408B2 (en) * 2002-10-03 2007-05-29 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
BRPI0408774A (pt) * 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
DK1628749T3 (da) 2003-05-30 2019-09-16 Vgxi Inc Anordninger og fremgangsmåder til biomateriel produktion
EP1687432A4 (en) 2003-11-13 2008-08-27 Sloan Kettering Inst Cancer COMPOSITIONS AND METHODS FOR SYNERGISTIC INDUCTION OF ANTITUMOR IMMUNITY
EP2316331B1 (en) * 2003-12-09 2016-06-29 Dexcom, Inc. Signal processing for continuous analyte sensor
GB0401876D0 (en) 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
CA3184778A1 (en) * 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
AU2013203229C1 (en) * 2006-07-28 2015-10-29 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US20090304711A1 (en) 2006-09-20 2009-12-10 Drew Pardoll Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8871211B2 (en) * 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
ATE534661T1 (de) * 2006-10-12 2011-12-15 Angeletti P Ist Richerche Bio Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
WO2008053573A1 (fr) * 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
US20090004716A1 (en) 2007-05-23 2009-01-01 Vgx Pharmaceuticlas, Inc. Compositions comprising high concentration of biologically active molecules and processes for preparing the same
US8829174B2 (en) 2008-10-29 2014-09-09 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
US8961994B2 (en) 2008-11-17 2015-02-24 Vgx Pharmaceuticals, Llc DNA constructs eliciting immune response against flavivirus and effective adjuvants
WO2010068680A1 (en) 2008-12-10 2010-06-17 Mount Sinai School Of Medicine Of New York University Thelper cell type 17 lineage-specific adjuvants, compositions and methods
CA2653478A1 (en) 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
ES2533228T3 (es) 2009-06-09 2015-04-08 Vaxon Biotech Identificación, optimización y uso de epítopos compartidos de HLA-B*0702 para inmunoterapia
WO2011020119A2 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
WO2011073901A1 (en) 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers
AU2011213559B2 (en) * 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
EP2558109A4 (en) * 2010-04-16 2014-09-24 Bellicum Pharmaceuticals Inc METHOD FOR TREATING HARD TUMORS
ES2664872T3 (es) * 2010-06-18 2018-04-23 Taiho Pharmaceutical Co., Ltd Moduladores PRPK-TPRKB y sus usos
MX346784B (es) 2010-11-12 2017-03-31 Inovio Pharmaceuticals Inc Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
US20140236070A1 (en) * 2011-07-29 2014-08-21 Kate Broderick Linear expression cassettes and uses thereof
RU2737765C2 (ru) * 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
PL2931304T3 (pl) * 2012-12-13 2021-11-08 The Trustees Of The University Of Pennsylvania Szczepionka wt1
ES2721159T3 (es) 2012-12-14 2019-07-29 Biontech Rna Pharmaceuticals Gmbh Antígenos asociados a tumor independientes de MHC novedosos
WO2014144885A2 (en) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same

Similar Documents

Publication Publication Date Title
JP2021100944A5 (enExample)
ES2848064T3 (es) Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas
Lo et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies
JP2021100944A (ja) ガンワクチン及びそれを用いた治療方法
CN104640565B (zh) 乙型肝炎病毒核心蛋白和表面抗原蛋白以及包含其的疫苗
JP2020039347A (ja) 新規多価ナノ粒子に基づくワクチン
JP2023533772A5 (enExample)
JP2019526580A5 (enExample)
KR20160105452A (ko) Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
HUP0103214A2 (hu) DNS-vakcinák
KR20170106453A (ko) 관문 억제제 및 백신 조합 및 면역요법을 위한 이들의 사용
Martin Caballero et al. Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7–dependent tumors
Yu et al. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice
JP2015533376A5 (enExample)
RU2021109510A (ru) Вакцинация с использованием альфа 3 домена mica/b для лечения рака
Pishraft-Sabet et al. Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96
JP2010506926A5 (enExample)
Öhlschläger et al. The combination of TLR‐9 adjuvantation and electroporation‐mediated delivery enhances in vivo antitumor responses after vaccination with HPV‐16 E7 encoding DNA
JP2014139185A5 (enExample)
Sokke Umeshappa et al. CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination
Shayeghpour et al. Hepatitis C virus DNA vaccines: a systematic review
Zhang et al. Hepatitis B virus core antigen epitopes presented by HLA‐A2 single‐chain trimers induce functional epitope‐specific CD8+ T‐cell responses in HLA‐A2· 1/Kb transgenic mice
Wang et al. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice
Kim et al. Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine
Cheng et al. Topical CpG oligodeoxynucleotide adjuvant enhances the adaptive immune response against influenza A infections